Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.65 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.65 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | GCK | P35557 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966191 | 0.86 | SCN3A (0.73) | SPHK2SPHK1SCN3ANR4A2TP53 | |
| SCHEMBL963826 | 0.86 | SCN3A (0.76) | SPHK2SPHK1SCN3ACD274BCHE | |
| SCHEMBL964037 | 0.83 | SPHK2 (0.67) | SPHK2SPHK1NR4A2NPC1RAB9A | |
| SCHEMBL964385 | 0.81 | MAOB (0.59) | NR4A2NPC1RAB9ACD274MAOB | |
| SCHEMBL8985630 | 0.80 | TP53 (0.58) | SPHK2SPHK1NR4A2NPC1RAB9A | |
| SCHEMBL964244 | 0.78 | SPHK2 (0.67) | SPHK2SPHK1SCN3ANR4A2MAOB | |
| SCHEMBL87713 | 0.77 | MAOB (0.59) | SCN3ANR4A2RAB9ABCHETP53 | |
| SCHEMBL4638863 | 0.76 | NR4A2 (0.77) | SPHK2SPHK1NR4A2NPC1RAB9A | |
| SCHEMBL4584070 | 0.75 | MEN1 (0.65) | SPHK2SPHK1 | |
| SCHEMBL20314087 | 0.75 | PRMT5 (0.55) | SPHK2SPHK1NR4A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | claimed |
| US-8445539-B2 | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-05-21 | — | — | US | claimed |
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-01-20 | — | — | US | claimed |
| EP-2222290-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-01 | — | — | EP | claimed |
| WO-2009080470-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-07-02 | — | — | WO | claimed |
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | disclosed |
| US-8445539-B2 | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-05-21 | — | — | US | disclosed |
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-01-20 | — | — | US | disclosed |
| EP-2222290-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009080470-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GABBR1, GABBR2, GABRA5 | SPHK2 4354/4885SPHK1 4298/4885SCN3A 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.